Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report
BackgroundTyrosine kinase inhibitors (TKIs) and immunotherapy have been proposed for advanced metastatic anaplastic thyroid cancer (ATC). We report a case of BRAF V600E-mutated ATC in which lenvatinib (L) plus pembrolizumab (P) enabled neoadjuvant treatment.Case presentationA male patient aged 65 ye...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2024-07-01
|
| Col·lecció: | Frontiers in Endocrinology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1389294/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|